FDA Approves DUPIXENT for Pediatric Eosinophilic Esophagitis, Expanding Treatment Options
The FDA has granted approval for DUPIXENT (dupilumab) to treat eosinophilic esophagitis (EoE) in children aged 1-11 years weighing at least 15 kg. The approval follows successful Phase III EoE KIDS trial results showing superior histological remission rates compared to placebo. This development represents a significant advancement in treating pediatric EoE, a condition affecting approximately 1 in 2,000 people.
ESO-101 Shows Promise in Phase II Trial for Eosinophilic Esophagitis
• EsoCap AG's ESO-101 demonstrated significant reduction in eosinophil counts in adults with eosinophilic esophagitis (EoE).
• The ACESO Phase II study showed 48% of patients achieved histological remission with ESO-101 compared to none in the placebo group.
• ESO-101, leveraging a novel drug delivery system, exhibited a favorable safety profile with no cases of candidiasis.
• The trial's results indicate ESO-101's potential for effective disease management where current treatment options are limited.
© Copyright 2025. All Rights Reserved by MedPath